JP7579281B2 - キナーゼ阻害剤の結晶性塩形態 - Google Patents

キナーゼ阻害剤の結晶性塩形態 Download PDF

Info

Publication number
JP7579281B2
JP7579281B2 JP2021571744A JP2021571744A JP7579281B2 JP 7579281 B2 JP7579281 B2 JP 7579281B2 JP 2021571744 A JP2021571744 A JP 2021571744A JP 2021571744 A JP2021571744 A JP 2021571744A JP 7579281 B2 JP7579281 B2 JP 7579281B2
Authority
JP
Japan
Prior art keywords
compound
xrpd pattern
following
theta scale
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535072A5 (enExample
JP2022535072A (ja
Inventor
フレネル デモリン，
ハリド シャー，
サーガル シャキャ，
ピーター ウォン，
コートニー エス． ジョンソン，
メラニー ジャネール ベビル，
ステファン ディー． ペアレント，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2022535072A publication Critical patent/JP2022535072A/ja
Publication of JP2022535072A5 publication Critical patent/JP2022535072A5/ja
Application granted granted Critical
Publication of JP7579281B2 publication Critical patent/JP7579281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021571744A 2019-06-03 2019-12-12 キナーゼ阻害剤の結晶性塩形態 Active JP7579281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
US62/856,404 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (3)

Publication Number Publication Date
JP2022535072A JP2022535072A (ja) 2022-08-04
JP2022535072A5 JP2022535072A5 (enExample) 2022-12-19
JP7579281B2 true JP7579281B2 (ja) 2024-11-07

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571744A Active JP7579281B2 (ja) 2019-06-03 2019-12-12 キナーゼ阻害剤の結晶性塩形態

Country Status (22)

Country Link
US (1) US20230052703A1 (enExample)
EP (1) EP3976587B1 (enExample)
JP (1) JP7579281B2 (enExample)
KR (1) KR102826380B1 (enExample)
CN (1) CN113939503B (enExample)
AU (1) AU2019449809B2 (enExample)
BR (1) BR112021024300A2 (enExample)
CA (1) CA3139148A1 (enExample)
CL (1) CL2021003205A1 (enExample)
CO (1) CO2021017343A2 (enExample)
CR (1) CR20210616A (enExample)
DO (1) DOP2021000236A (enExample)
ES (1) ES3008963T3 (enExample)
GE (2) GEP20247655B (enExample)
IL (1) IL288484A (enExample)
MA (1) MA56001A (enExample)
MX (1) MX2021014773A (enExample)
PE (1) PE20220962A1 (enExample)
PH (1) PH12021553020A1 (enExample)
SG (1) SG11202111978VA (enExample)
WO (1) WO2020247019A1 (enExample)
ZA (1) ZA202108034B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
US20250368606A1 (en) 2021-12-22 2025-12-04 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021511360A (ja) 2018-01-26 2021-05-06 エグゼリクシス， インコーポレイテッド キナーゼ依存的障害を処置するための化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
ES2598530T3 (es) * 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MA48776A (fr) * 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021511360A (ja) 2018-01-26 2021-05-06 エグゼリクシス， インコーポレイテッド キナーゼ依存的障害を処置するための化合物

Also Published As

Publication number Publication date
PH12021553020A1 (en) 2023-08-23
ES3008963T3 (en) 2025-03-25
EP3976587A1 (en) 2022-04-06
EP3976587B1 (en) 2024-12-04
BR112021024300A2 (pt) 2022-01-11
AU2019449809B2 (en) 2026-02-05
SG11202111978VA (en) 2021-11-29
CN113939503A (zh) 2022-01-14
CN113939503B (zh) 2024-05-07
IL288484A (en) 2022-01-01
KR102826380B1 (ko) 2025-06-26
AU2019449809A1 (en) 2021-12-16
DOP2021000236A (es) 2022-04-18
CA3139148A1 (en) 2020-12-10
GEAP202415849A (en) 2024-03-11
KR20220016117A (ko) 2022-02-08
PE20220962A1 (es) 2022-06-10
US20230052703A1 (en) 2023-02-16
EP3976587C0 (en) 2024-12-04
JP2022535072A (ja) 2022-08-04
MA56001A (fr) 2022-04-06
WO2020247019A1 (en) 2020-12-10
CO2021017343A2 (es) 2022-01-17
GEP20247655B (en) 2024-08-26
ZA202108034B (en) 2025-02-26
CR20210616A (es) 2022-03-22
CL2021003205A1 (es) 2022-09-30
MX2021014773A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
JP7783870B2 (ja) キナーゼ阻害剤の結晶性形態及び塩形態
JP7579281B2 (ja) キナーゼ阻害剤の結晶性塩形態
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
EA048718B1 (ru) Кристаллические солевые формы ингибитора киназы
HK40067664B (zh) 激酶抑制剂的结晶盐形式
OA20944A (en) Crystalline salt forms of a kinase inhibitor
HK40061293B (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
BR122025022768A2 (pt) Formas cristalinas, sais de ácido clorídrico e ácido fosfórico cristalinos, composição farmacêutica e usos relacionados
HK40067664A (en) Crystalline salt forms of a kinase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241025

R150 Certificate of patent or registration of utility model

Ref document number: 7579281

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150